Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel

Anticancer Research

Volumn 25, Issue 3 C, 2005, Pages 2367-2379

  Wang, Zhuo ^a   Goulet III, Robert ^a   Stanton, Katie J ^a   Sadaria, Miral ^a   Nakshatri, Harikrishna ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bcl xL; Breast cancer; c FLIP; Docetaxel; NF B; Paclitaxel

Indexed keywords

2 METHOXYANTIMYCIN A3; 3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; C INHIBITOR OF APOPTOSIS PROTEIN 2; CARBOXYFLUORESCEIN; CASPASE 8; CASPASE 9; DOCETAXEL; FLICE INHIBITORY PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; PACLITAXEL; PROTEIN BCL XL; PROTEIN INHIBITOR; TETRAZOLE DERIVATIVE; TRYPAN BLUE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIMYCIN A; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL DIVISION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS;

EID: 22944468183     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hudis CA: Current status and future directions in breast cancer therapy. Clin Breast Cancer 4: S70-75, 2003.
2. Garces CA and Cance WG: Neoadjuvant chemotherapy of breast cancer. Am Surg 70: 565-569, 2004.
3. Nowak A K, Wilcken NR, Stockler MR, Hamilton A and Ghersi D: Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 5: 372-380, 2004.
4. Yardley DA: Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer. Semin Oncol 31: 37-44, 2004.
5. Moos PJ and Fitzpatrick FA: Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 95: 3896-3901, 1998.
6. Bhalla KN: Microtubule-targeted anticancer agents and apoptosis. Oncogene 22: 9075-9086, 2003.
7. Orr GA, Verdier-Pinard P, McDaid H and Horwitz SB: Mechanisms of Taxol resistance related to microtubules. Oncogene 22: 7280-7295, 2003.
8. Karin M and Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227, 2002.
9. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246, 2001.
10. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639, 1997.
11. Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell 109: S81-96, 2002.
12. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nature Rev Cancer 2: 301-310, 2002.
13. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr, Sledge GW Jr and Nakshatri H: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19: 4159-4169, 2000.
14. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417, 1999.
15. Zhang H, Morisaki T, Nakahara C, Matsunaga H, Sato N, Nagumo F, Tadano J and Katano M: PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 22: 2088-2096, 2003.
16. Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS, Ali S and Nakshatri H: Tumor necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. Br J Cancer 90: 853-859, 2004.
17. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, Zhang KY and Hockenbery DM: Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3: 183-191, 2001.
18. Martin SS, Ridgeway AG, Pinkas J, Lu Y, Reginato MJ, Koh, EY, Michelman M, Daley GQ, Brugge JS and Leder PA: Cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 23: 4641-4645, 2004.
19. Stegh AH, Barnhart BC, Volkland J, Algeciras-Schimnich A, Ke N, Reed JC and Peter ME: Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein. J Biol Chem 277: 4351-4360, 2002.
20. Scaffidi C, Schmitz I, Krammer PH and Peter ME: The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274: 1541-1548, 1999.
21. Pozarowski P, Halicka DH and Darzynkiewicz Z: NF-kappaB inhibitor sesquiterpene parthenolide induces concurrently atypical apoptosis and cell necrosis: difficulties in identification of dead cells in such cultures. Cytometry 54A: 118-124, 2003.
22. Nakshatri H, Rice SE and Bhat-Nakshatri P: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23: 7330-7344, 2004.
23. Grant DS, Williams TL, Zahaczewsky M and Dicker AP: Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104: 121-129, 2003.
24. Lin HL, Liu TY, Chau GY, Lui WY and Chi CW: Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 89: 983-994, 2000.
25. Janicke RU, Ng P, Sprengart ML and Porter AG: Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 273: 15540-15545, 1998.
26. Debatin KM and Krammer PH: Death receptors in chemotherapy and cancer. Oncogene 23: 2950-2966, 2004.
27. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998.
28. Fotin-Mleczek M, Henkler F, Hausser A, Glauner H, Samel,D, Graness A, Scheurich P, Mauri D and Wajant H: Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation. J Biol Chem 279: 677-685, 2004.
29. Macmillan-Crow LA and Cruthirds DL: Invited review: manganese superoxide dismutase in disease. Free Radic Res 34: 325-336, 2001.
30. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
31. Li JJ and Oberley LW: Overexpression of manganese-containing superoxide dismutase confers resistance to the cytotoxicity of tumor necrosis factor alpha and/or hyperthermia. Cancer Res 57: 1991-1998, 1997.
32. Shtil AA, Mandlekar S, Yu R, Walter RJ, Hagen K, Tan TH, Roninson IB and Kong AN: Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene 18: 377-384, 1999.
33. Manna SK, Zhang HJ, Yan T, Oberley LW and Aggarwal BB: Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem 273: 13245-13254, 1998.
34. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson C B and Recant WM: Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 3: 230-237, 1997.